Drug Trial Radar · NCT06494644
A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.
Last checked: Nov 19, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Jul 23, 2024
Primary completion
Oct 5, 2024
Study completion Oct 5, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will evaluate the pharmacokinetics (PK) of AZD6793 when administered alone and in combination with itraconazole in healthy adult participants.
Conditions
- Healthy Participants
Interventions
AZD6793Drug
Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.
ItraconazoleDrug
Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.
AZD6793+ ItraconazoleDrug
Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum plasma drug concentration (Cmax)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
- Area under plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
- Area under plasma concentration-time curve from time 0 to infinity (AUCinf)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
- Apparent total body clearance (CL/F)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
- Terminal elimination half-life (t1/2λz)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
- Time to reach maximum observed concentration (tmax)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
- Apparent volume of distribution during the terminal phase (Vz/F)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
- Ratio Area under plasma concentration-time curve from time 0 to infinity (RAUCinf)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
- Ratio Area under plasma concentration-time curve from time 0 to the last quantifiable concentration (RAUClast)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
- Ratio Maximum plasma drug concentration (RCmax)Time frame: Post-dose on Day 1 to Day 3; and Day 8 to Day 11
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.